This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
Aug. 12, 2013 /PRNewswire/ -- Harwood Feffer LLP (
www.hfesq.com) is investigating potential claims against the board of directors of Optimer Pharmaceuticals, Inc. ("Optimer" or the "Company") (NASDAQ: OPTR) concerning the proposed acquisition of the Company by Cubist Pharmaceuticals, Inc. ("Cubist").